scholarly journals Downregulation of cytokeratin 18 is associated with paclitaxel-resistance and tumor aggressiveness in prostate cancer

2016 ◽  
Vol 48 (4) ◽  
pp. 1730-1736 ◽  
Author(s):  
BO YIN ◽  
MO ZHANG ◽  
YU ZENG ◽  
YOUQIANG LI ◽  
CHAO ZHANG ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Aggressiveness ◽  
Paclitaxel Resistance ◽  
Cytokeratin 18

scholarly journals The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines

The Prostate ◽  
2007 ◽  
Vol 67 (9) ◽  
pp. 955-967 ◽  
Author(s):  
Masashi Takeda ◽  
Atsushi Mizokami ◽  
Kiminori Mamiya ◽  
You Qiang Li ◽  
Jian Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Cancer Cell Lines ◽  
Paclitaxel Resistance ◽  
Prostate Cancer Cell Lines

MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms

The Prostate ◽  
2010 ◽  
Vol 70 (14) ◽  
pp. 1501-1512 ◽  
Author(s):  
Keitaro Kojima ◽  
Yasunori Fujita ◽  
Yoshinori Nozawa ◽  
Takashi Deguchi ◽  
Masafumi Ito
Keyword(s):  
Prostate Cancer ◽  
Hormone Refractory Prostate Cancer ◽  
Paclitaxel Resistance ◽  
Pc3 Cells ◽  
Hormone Refractory

scholarly journals Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Hamdy E. A. Ali ◽  
Pei-Yau Lung ◽  
Andrew B. Sholl ◽  
Shaimaa A. Gad ◽  
Juan J. Bustamante ◽  
...  
Keyword(s):  
Gene Expression ◽  
Prostate Cancer ◽  
African American ◽  
Cancer Patients ◽  
Tumor Aggressiveness

MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1

2017 ◽  
Vol 36 (3) ◽  
pp. 357-365 ◽  
Author(s):  
Lei Chen ◽  
Hongwen Cao ◽  
Yigeng Feng
Keyword(s):  
Prostate Cancer ◽  
Paclitaxel Resistance

scholarly journals Study of testosterone as a predictor of tumor aggressiveness in patients with prostate cancer

2013 ◽  
Vol 39 (2) ◽  
pp. 173-181 ◽  
Author(s):  
Pedro Henrique Oliveira Cabral ◽  
Marcelo Wassano Iwamoto ◽  
Victor Silvestre Soares Fanni ◽  
Luciano da Rocha Barros ◽  
Sandro Nassar Cardoso ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Aggressiveness

Overexpression of TACC3 is correlated with tumor aggressiveness and poor prognosis in prostate cancer

2017 ◽  
Vol 486 (4) ◽  
pp. 872-878 ◽  
Author(s):  
Qiji Li ◽  
Liping Ye ◽  
Wei Guo ◽  
Min Wang ◽  
Shuai Huang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Poor Prognosis ◽  
Tumor Aggressiveness

scholarly journals MTA1-Dependent Anticancer Activity of Gnetin C in Prostate Cancer

Nutrients ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 2096 ◽  
Author(s):  
Avinash Kumar ◽  
Kshiti Dholakia ◽  
Gabriela Sikorska ◽  
Luis A. Martinez ◽  
Anait S. Levenson
Keyword(s):  
Prostate Cancer ◽  
Intraepithelial Neoplasia ◽  
Inhibitory Effect ◽  
Tumor Aggressiveness ◽  
Therapeutic Approaches ◽  
Anticancer Efficacy ◽  
Anticancer Effects ◽  
And Migration

The overexpression of metastasis-associated protein 1 (MTA1) in prostate cancer (PCa) contributes to tumor aggressiveness and metastasis. We have reported the inhibition of MTA1 by resveratrol and its potent analog pterostilbene in vitro and in vivo. We have demonstrated that pterostilbene treatment blocks the progression of prostatic intraepithelial neoplasia and adenocarcinoma in mouse models by inhibiting MTA1 expression and signaling. In the current study, we investigated the MTA1 targeted anticancer effects of Gnetin C, a resveratrol dimer, in comparison with resveratrol and pterostilbene. Using DU145 and PC3M PCa cells, we found that Gnetin C downregulates MTA1 more potently than resveratrol and pterostilbene. Further, Gnetin C demonstrated significant MTA1-mediated inhibitory effect on cell viability, colony formation, and migration, while showing a more potent induction of cell death than resveratrol or pterostilbene. In addition, we identified Gnetin C-induced substantial ETS2 (erythroblastosis E26 transformation-specific 2) downregulation, which is not only MTA1-dependent, but is also independent of MTA1 as a possible mechanism for the superior anticancer efficacy of Gnetin C in PCa. Together, these findings underscore the importance of novel potent resveratrol dimer, Gnetin C, as a clinically promising agent for the future development of chemopreventive and possibly combinatorial therapeutic approaches in PCa.

Sign in / Sign up

Export Citation Format

Share Document